Sunday 18 October 2026
Export NAUT’s income statement to Excel — free account
Nautilus Biotechnology, Inc.
NAUT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 8.33% and free cash flow fell 3.16%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.06
0.10
−4.63%
Follow NAUT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (17.32) | |
P/B ratio |
— | — | — | 1.81 | |
Price to Tangible BV |
— | — | — | 1.81 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (3.06) | |
EV/FCF |
— | — | — | (2.96) | |
Quick Ratio |
14.63 | 13.00 | 11.49 | 9.73 | |
Current Ratio |
14.95 | 13.33 | 11.85 | 10.14 | |
Net Debt/EBITDA |
9.28 | 7.41 | 6.51 | 5.81 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.90 | 0.89 | 0.95 | |
Capex/Depreciation |
(0.32) | (0.17) | (0.36) | (0.35) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 5,059.47% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 3,328.95% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 609.47% | |
Graham Net Nets |
— | — | — | 0.23 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (24.06%) | |
Free Cash Flow Yield |
— | — | — | (21.81%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.09) | (0.10) | (0.10) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.10) | (0.11) | (0.11) | |
Cash per Share |
1.04 | 0.82 | 0.76 | 0.66 | |
Shareholders Equity per Share |
1.34 | 1.24 | 1.14 | 1.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.34 | 1.24 | 1.14 | 1.03 | |
Free Cash Flow |
(11.45) | (12.62) | (13.61) | (14.18) | |
Working Capital |
125.34 | 98.01 | 90.49 | 78.99 | |
Capital Expenditures |
(0.42) | (0.24) | (0.51) | (0.45) | |
Net Current Asset Value |
102.55 | 71.82 | 65.47 | 55.16 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 2.39 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
1.19 | 0.97 | 1.01 | 1.03 | |
Average Assets |
230.31 | 216.93 | 202.73 | 188.38 | |
Average Common Equity |
196.29 | 182.85 | 169.43 | 156.10 |
Columns are period end dates